Data / Drug companies / Acella Pharmaceuticals, LLC
Acella Pharmaceuticals, LLC: 40 products in the FDA NDC directory, labeler code 42192
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Acella Pharmaceuticals, LLC (labeler code 42192) lists 40 products in the FDA National Drug Code Directory, covering 17 finished drugs by generic name. By type: 40 prescription drugs. Its main marketing category is other unapproved drugs. The newest product started marketing on October 31, 2026.
The request: Watch Acella Pharmaceuticals, LLC (FDA labeler code 42192): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 42192
- Products in commercial distribution
- 40
- Packages
- 65
- Finished drugs by generic name
- 17
- Prescription products
- 40
- Over the counter products
- 0
- Flagged as original packager
- 28 of 28 products that carry the flag
- Started marketing in the last 12 months
- 2
- Products with a marketing end date set
- 3
- Earliest marketing start
- October 1, 1990
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Other unapproved drugs | 30 | 75% |
| Generic drugs (ANDA) | 7 | 17.5% |
| New drug applications (NDA) | 2 | 5% |
| Authorized generics (NDA) | 1 | 2.5% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 40 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 9 | 22.5% |
| Solution | 6 | 15% |
| Liquid | 5 | 12.5% |
| Cream | 4 | 10% |
| Capsule, gelatin coated | 3 | 7.5% |
| Syrup | 2 | 5% |
| Rinse | 2 | 5% |
| Kit | 2 | 5% |
| Gel | 1 | 2.5% |
| Suspension | 1 | 2.5% |
| Tablet, coated | 1 | 2.5% |
| Capsule, coated | 1 | 2.5% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| NP Thyroid 180 | 42192-376 | Tablet | Other unapproved drugs | October 31, 2026 |
| Baclofen | 42192-631 | Solution | New drug applications (NDA) | October 26, 2026 |
| Brompheniramine Maleate, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide | 42192-630 | Syrup | Generic drugs (ANDA) | February 1, 2025 |
| Pyridostigmine Bromide | 42192-626 | Solution | Generic drugs (ANDA) | October 9, 2023 |
| Levonorgestrel and ethinyl estradiol | 42192-623 | Kit | New drug applications (NDA) | August 21, 2023 |
| Phenytoin sodium | 42192-614 | Injection | Generic drugs (ANDA) | December 1, 2021 |
| Nicotinamide | 42192-374 | Tablet | Other unapproved drugs | May 25, 2021 |
| Naproxen | 42192-619 | Suspension | Authorized generics (NDA) | November 12, 2020 |
| Doxycycline | 42192-501 | Tablet, coated | Generic drugs (ANDA) | August 21, 2020 |
| Ciclopirox | 42192-715 | Solution | Generic drugs (ANDA) | November 4, 2019 |
| NP Thyroid 120 | 42192-328 | Tablet | Other unapproved drugs | June 12, 2017 |
| Sodium Sulfacetamide 9.8% and Sulfur 4.8% Cleanser | 42192-156 | Liquid | Other unapproved drugs | December 12, 2016 |
| NP Thyroid 15 | 42192-327 | Tablet | Other unapproved drugs | November 16, 2016 |
| Brompheniramine Maleate, Pseudoephedrine Hydrochloride, Dextromethorphan Hydrobromide | 42192-607 | Syrup | Generic drugs (ANDA) | September 21, 2016 |
| Hydroquinone 4% | 42192-151 | Cream | Other unapproved drugs | September 10, 2014 |
| Sodium Sulfacetamide 10 Sulfur 2 cream | 42192-150 | Cream | Other unapproved drugs | August 21, 2014 |
| Sodium sulfacetamide, sulfur | 42192-149 | Cream | Other unapproved drugs | August 14, 2014 |
| Sodium Sulfacetamide 10 Sulfur 2 Cleanser | 42192-147 | Solution | Other unapproved drugs | August 14, 2014 |
| Sodium sulfacetamide, sulfur | 42192-139 | Cream | Other unapproved drugs | June 11, 2014 |
| Sodium Sulfacetamide 9 Sulfur 4.5 Wash | 42192-144 | Rinse | Other unapproved drugs | March 20, 2013 |
| Gabapentin | 42192-608 | Solution | Generic drugs (ANDA) | October 1, 2012 |
| Sodium Sulfacetamide 10 Sulfur 5 Cleanser | 42192-136 | Rinse | Other unapproved drugs | April 20, 2012 |
| Ciclopirox | 42192-714 | Kit | Other unapproved drugs | October 10, 2011 |
| Salicylic acid | 42192-135 | Liquid | Other unapproved drugs | October 10, 2011 |
| Hyoscyamine Sulfate TAB | 42192-340 | Tablet | Other unapproved drugs | May 19, 2011 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.